Aetiology and natural history of Parkinson's disease.
作者信息
Pearce J M
出版信息
Br Med J. 1978 Dec 16;2(6153):1664-6. doi: 10.1136/bmj.2.6153.1664-a.
Abstract
摘要
相似文献
1
Aetiology and natural history of Parkinson's disease.帕金森病的病因及自然史。
Br Med J. 1978 Dec 16;2(6153):1664-6. doi: 10.1136/bmj.2.6153.1664-a.
2
Understanding Parkinson's disease.
Sci Am. 1997 Jan;276(1):52-9. doi: 10.1038/scientificamerican0197-52.
3
[Drug therapy in Parkinson's disease].[帕金森病的药物治疗]
Ned Tijdschr Geneeskd. 1999 Jan 30;143(5):234-40.
4
[L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
Acta Neurol Quad (Napoli). 1981;42:212-5.
5
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.左旋多巴可增强帕金森病患者黑质网状部的突触可塑性。
Brain. 2009 Feb;132(Pt 2):309-18. doi: 10.1093/brain/awn322. Epub 2008 Dec 2.
6
[ Is Parkinson's disease due to deficiency of dopamine?].[帕金森病是由于多巴胺缺乏所致吗？]
Duodecim. 2005;121(7):782-3; author reply 783-4.
7
[Will the mystery of Parkinson's disease be resolved?].帕金森病之谜会被解开吗？
Duodecim. 2005;121(3):275-84.
8
Parkinson's disease and levodopa. A five-year follow-up and review.帕金森病与左旋多巴。五年随访及综述。
West J Med. 1974 Sep;121(3):188-206.
9
Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.帕金森病中多巴胺的基础研究与黑质纹状体多巴胺通路的发现：一位见证者的视角
Neurodegener Dis. 2008;5(3-4):114-7. doi: 10.1159/000113678. Epub 2008 Mar 6.
10
Current views on Parkinson's disease.关于帕金森病的当前观点。
Can J Neurol Sci. 1983 Feb;10(1):11-5. doi: 10.1017/s0317167100044498.
引用本文的文献
1
The 2022 On-site Padua Days on Muscle and Mobility Medicine hosts the University of Florida Institute of Myology and the Wellstone Center, March 30 - April 3, 2022 at the University of Padua and Thermae of Euganean Hills, Padua, Italy: The collection of abstracts.2022年肌肉与运动医学帕多瓦现场日活动由佛罗里达大学肌病学研究所和韦尔斯通中心主办，于2022年3月30日至4月3日在意大利帕多瓦大学和帕多瓦尤加尼山温泉浴场举行：摘要征集。
Eur J Transl Myol. 2022 Mar 10;32(1):10440. doi: 10.4081/ejtm.2022.10440.
2
Systemic factors and mortality in elderly patients with pressure ulcers.老年压疮患者的全身因素与死亡率
Int Wound J. 2015 Jun;12(3):254-9. doi: 10.1111/iwj.12086. Epub 2013 May 21.
3
Levodopa: long-term impact on Parkinson's disease.左旋多巴：对帕金森病的长期影响。
Br Med J (Clin Res Ed). 1981 Feb 7;282(6262):417-8. doi: 10.1136/bmj.282.6262.417.
本文引用的文献
1
Parkinsonism: onset, progression and mortality.帕金森症：发病、进展与死亡率
Neurology. 1967 May;17(5):427-42. doi: 10.1212/wnl.17.5.427.
2
The prevalence, natural history and dementia of Parkinson's disease.帕金森病的患病率、自然史与痴呆
Brain. 1966 Sep;89(3):429-48. doi: 10.1093/brain/89.3.429.
3
4
Letter: Mental changes in Parkinsonism.信函：帕金森病中的精神变化。
Br Med J. 1974 May 25;2(5916):445. doi: 10.1136/bmj.2.5916.445.
5
Letter: G.A.B.A. and Huntington's chorea.信件：γ-氨基丁酸与亨廷顿舞蹈病
Lancet. 1973 Dec 29;2(7844):1499-500. doi: 10.1016/s0140-6736(73)92765-7.
6
Glutamic-acid decarboxylase and choline acetylase in Huntington's chorea and Parkinson's disease.亨廷顿舞蹈病和帕金森病中的谷氨酸脱羧酶与胆碱乙酰化酶
Lancet. 1973 Sep 15;2(7829):622-3.
7
Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.左旋多巴治疗帕金森病五年。100例患者的治疗结果与生存率
Ann Intern Med. 1975 Oct;83(4):456-63. doi: 10.7326/0003-4819-83-4-456.
8
Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.接受左旋多巴联合脱羧酶抑制剂治疗的帕金森病患者的死亡率。
Eur Neurol. 1976;14(5):321-8. doi: 10.1159/000114756.
9
Fenfluramine hydrochloride treatment of parkinsonism.盐酸芬氟拉明治疗帕金森病。
Arch Neurol. 1977 Apr;34(4):255-6. doi: 10.1001/archneur.1977.00500160069016.
10
Possible GABA-mediated control of dopamine-dependent behavioural effects from the nucleus accumbens of the rat.大鼠伏隔核中可能存在的γ-氨基丁酸介导的对多巴胺依赖性行为效应的控制。
Psychopharmacology (Berl). 1976 Sep 17;49(2):173-8. doi: 10.1007/BF00427286.
Zotero 插件